These findings may be comparable to other investigations showing distinct pathways associated with cognitive decline in AD at the transcriptomic, proteomic, and methylation levels in brain tissue without overlapping correlation with AD pathology [73–77], highlighting the heterogeneity of downstream molecular processes from what is putatively considered the upstream etiological agents, namely Aβ and tau. This evidence concerns the gene MAPT and Alzheimer disease.